Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) Shares Outstanding (Weighted Average) (2020 - 2026)

Design Therapeutics' Shares Outstanding (Weighted Average) history spans 2 years, with the latest figure at $45.9 million for Q4 2021.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 190.8% to $45.9 million in Q4 2021 year-over-year; TTM through Dec 2021 was $45.9 million, a 190.8% increase, with the full-year FY2021 number at $45.9 million, up 190.8% from a year prior.
  • Shares Outstanding (Weighted Average) hit $45.9 million in Q4 2021 for Design Therapeutics, down from $55.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for DSGN hit a ceiling of $55.2 million in Q3 2021 and a floor of $15.7 million in Q1 2020.